Table 2.
Plasma and CSF TDP-43/pTDP-43 concentrations in different groups.
| Subgroup items | TDP-43 levels (pg/ml) | pTDP-43 levels (relative unit) | P-value | ||
|---|---|---|---|---|---|
| Plasma | CSF | Plasma (%) | CSF (%) | P1/P2/P3/P4 | |
| Group | |||||
| ALS (n = 69) | 82.98 (102.65) | 29.67 (18.05) | 1.19 (0.65) | 2.45 (1.77) | <0.001/0.086/ <0.001/0.065 |
| HC (n = 59) | 23.09 (15.23) | 25.75 (24.25) | 0.58 (0.55) | 1.91 (1.97) | |
| Gender in ALS Group | |||||
| Male (n = 46) | 83.82 (102.04) | 29.80 (19.56) | 1.16 (0.66) | 2.46 (1.19) | 0.410/0.462/0.223/0.800 |
| Female (n = 23) | 82.98 (121.09) | 26.98 (17.49) | 1.32 (0.74) | 2.39 (1.01) | |
| Site of onset in ALS group | |||||
| Bulbar (n = 10) | 77.02 (68.32) | 32.36 (22.21) | 1.16 (0.42) | 1.97 (0.85)* | 0.179/0.357/0.373/0.159 |
| Spinal (n = 59) | 88.41 (108.86) | 29.67 (17.90) | 1.19 (0.71) | 2.52 (1.16)* | |
Data are expressed as median (IQR).
*
Data are expressed as mean (SD).
CSF, cerebrospinal fluid; ALS, amyotrophic lateral sclerosis; HC, healthy control. P1 and P2 represent the statistically significant of TDP-43 in plasma and CSF between subgroups which expressed as P-value, respectively. P3 and P4 represent the statistically significant of pTDP-43 in plasma and CSF between subgroups which expressed as P-value, respectively.